Dr. Temitayo O. Chidi, MD, PHD
Child Neurology (Neurology with Special Qualifications in Child Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Wisconsin School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 42
Licensed in California since 2019, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Wisconsin School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology with Special Qualifications in Child Neurology Physician primary
VA license 0101250149 · CA license C166590 (first issued 2019; current) -
Sleep Medicine (Psychiatry & Neurology) Physician
CA license C166590 (first issued 2019; current) · DC license MD040137 · MD license D76678 · VA license 0101250149
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of California Davis Medical Center Sacramento, CA
Medical groups
- Regents of the Univ of Ca (1,584 clinicians)
- Regents of the University of California (567 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 42
- Services billed
- 81
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Zolpidem Tartrate Other prescribers in Sacramento, CA | 19 |
| Mirtazapine Other prescribers in Sacramento, CA | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 27 payments worth $3,204 in total to this clinician.
| Acadia Pharmaceuticals Inc | $1,996 |
|---|---|
| Jazz Pharmaceuticals Inc. | $431 |
| Axsome Therapeutics, Inc. | $224 |
| Neurelis, Inc. | $157 |
| Sk Life Science, Inc. | $136 |
| Harmony Biosciences LLC | $88.18 |
| UCB, Inc. | $78.00 |
| Corium, LLC | $49.63 |
| Food and Beverage | $1,704 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $1,500 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Acadia Pharmaceuticals Inc Dec 3, 2025 | Compensation for services other than consulting (speaking, faculty) DAYBUE · RETT SYNDROME | $1,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $86,641 in research payments for these studies, mostly to the institutions running them.
- Phase 3 multicenter randomized doubleblind group sequential placebocontrolled study to assess efficacy and safety of rimegepant for the treatment of migraine with or without aura in children and adolescents 6 to 18 …
Pfizer Inc. - A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Jazz Pharmaceuticals Inc. - Phase 3 multicenter openlabel study to assess the longterm safety and tolerability of rimegepant for the acute treatment of migraine with or without aura in children and adolescents 6 to 18 years of age
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.